NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Merus N.V. (MRUS) Stock Analysis

Merus N.V. (MRUS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MRUS

$90.00

$0.00 (0.00%)

Last trade January 2, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRUS with… →

MRUS Key Statistics

As of Jan 2, 2026
Trading
Open
$90.00
Previous Close
$90.00
52-Week Range
33.19–97.14
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.06
Valuation
Market Cap
$6.83B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
120.59
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.28
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+112.77%
Dividend and dates
Avg Volume
1.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MRUS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025+114.03%
2024 (partial year)−0.10%

As of January 2, 2026.

MRUS Valuation vs Biotechnology Median

Median of 656 stocks
MetricMRUSBiotechnology medianvs median
P/S ratio120.5915.267.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Merus N.V. (MRUS) carries a market capitalisation of $6.83B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 260.

MRUS last closed at $90.00 on January 2, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $33.19 to $97.14. The latest close sits 171.17% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $56.61M. Profit margin runs at 0%. Trailing earnings per share are −5.28.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 120.59 times revenue. On price-to-sales that is 7.9 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.06. Daily returns over the trailing 1 year annualize to a volatility of 66.32%. Over the trailing twelve months the price has returned +112.77%.

Growth & Income

No dividend is on file for MRUS.

The record holds one complete calendar year, 2025, which returned +114.03%. So far in 2026 the price is 0.00%.

Peer Comparison

Merus N.V. (MRUS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Merus N.V. MRUS $6.83B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Merus N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of January 2, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

Visit website →